<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 19, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01745770</url>
  </required_header>
  <id_info>
    <org_study_id>SAT-25/UCA</org_study_id>
    <nct_id>NCT01745770</nct_id>
  </id_info>
  <brief_title>TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)</brief_title>
  <official_title>Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With Three Times Daily 1000 mg Mesalazine Versus Three Times Daily 2x500 mg Mesalazine in Patients With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to proof whether TID 1000 mg mesalazine is non-inferior to TID
      2x 500 mg mesalazine in the treatment of patients with acute ulcerative colitis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of clinical remission</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients with clinical remission at week 8 compared to baseline. Clinical remission includes normalisation of stool frequency and absence of blood in stools</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of stools per week</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bloody stools per week</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first resolution of clinical symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Times to first resolution of symptoms defined as the periods from the day of first administration of trial medication , until the
First of at least 3 consecutive days each with =&lt; 3 stools/day
First of at least 3 consecutive days each with no bloody stools/day,
First of at least 3 consecutive days each with =&lt; 3 stools/day, all without blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Active Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine - TID 1000 mg</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine - TID 2x 500 mg</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Men or women aged 18 to 75 years

          -  Active ulcerative colitis, except proctitis limited to 15 cm ab ano,   confirmed by
             endoscopy and histology

        Exclusion Criteria:

          -  Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis,
             diverticular disease associated colitis, microscopic colitis (i.e., collagenous
             colitis and lymphocytic colitis)

          -  Toxic megacolon

          -  Screening stool positive for germs causing bowel disease

          -  Malabsorption syndromes

          -  Celiac disease

          -  Other inflammatory or bleeding disorders of the colon and intestine, or diseases that
             may cause diarrhoea or gastrointestinal bleeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tanju Nacak, Dr.</last_name>
    <phone>+49 (0)761 1514</phone>
    <phone_ext>187</phone_ext>
    <email>nacak@drfalkpharma.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Axel Dignaß, Prof. Dr.</last_name>
    <phone>+49 (0)69 953322</phone>
    <phone_ext>01</phone_ext>
    <email>axel.dignass@fdk.info</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Med. Klinik 1 - Markus-Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Dignaß, Prof. Dr.</last_name>
      <phone>+49 (0)69 953322</phone>
      <phone_ext>01</phone_ext>
      <email>axel.dignass@fdk.info</email>
    </contact>
    <investigator>
      <last_name>Axel Dignaß, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 5, 2013</lastchanged_date>
  <firstreceived_date>December 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
